Relmada Therapeutics (RLMD) Net Cash Flow (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Net Cash Flow data on file, last reported at $6.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 331.96% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 4794.63% increase from a year earlier, with the FY2025 full-year figure at -$360486.0, down 53.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.3 million, up from $2.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for RLMD reached as high as $23.5 million in Q1 2023 and fell as low as -$37.1 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$2.0 million across 5 years, with a median of $31133.0 in 2025.
• Across the five-year window, Net Cash Flow plunged 986.8% in 2022 and surged 4686.45% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$37.1 million in 2022, then surged by 93.24% to -$2.5 million in 2023, then surged by 194.61% to $2.4 million in 2024, then declined by 11.01% to $2.1 million in 2025, then soared by 197.33% to $6.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $6.3 million in Q1 2026, $2.1 million in Q4 2025, and $31133.0 in Q3 2025.